Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Urol Oncol. 2020 Jul 13;38(9):734.e1–734.e10. doi: 10.1016/j.urolonc.2020.05.015

Figure II:

Figure II:

Increasing age and number of comorbidities is associated with worsening overall survival in patients with prostate cancer across D’Amico risk groups, as well as for patients with locally advanced disease (clinical staging N>0 or T4) and metastatic disease.